NeoGenomics Laboratories
NeoGenomics Laboratories provides over 650 diagnostic tests, including DNA and RNA-based next-generation sequencing, and offers comprehensive oncology-focused testing to aid in the diagnosis and treatment of cancer. The company operates CAP-accredited and CLIA-certified laboratories across the U.S. and globally, and partners with pharmaceutical clients in clinical trials and drug development.
Diagnostic Tests Portfolio
NeoGenomics Laboratories provides a comprehensive portfolio of over 650 diagnostic tests. These tests cover key testing methodologies, including broad-panel DNA and RNA-based next-generation sequencing. The offerings support precision medicine decisions, particularly in patients with lung cancer, through both comprehensive and targeted diagnostic approaches.
Nationwide and Global Laboratory Network
NeoGenomics operates a network of CAP-accredited, CLIA-certified laboratories in key locations across the U.S., including Fort Myers, Tampa, Aliso Viejo, Carlsbad, San Diego, Research Triangle Park, Houston, Atlanta, Nashville, and Phoenix. Additionally, the company maintains global laboratories to extend its reach in providing high-standard diagnostic services.
Oncology-Focused Testing Solutions
NeoGenomics Laboratories offers a wide range of oncology-focused testing solutions. Their services include Neo Comprehensive™ tests for both hematologic malignancies (433 genes) and solid tumors (517 genes), the InVisionFirst®-Lung liquid biopsy for advanced NSCLC (37-gene panel), and the Early-stage NSCLC Panel—the only therapy selection panel explicitly designed for early-stage NSCLC patients.
Clinical Trial and Pharmaceutical Partnerships
NeoGenomics Laboratories partners with pharmaceutical clients in clinical trials and drug development. These collaborations are aimed at advancing the latest therapies and diagnostics, supporting their integration into clinical practice to improve patient outcomes.
Patient-Centric Services
Committed to enhancing patient care, NeoGenomics provides several patient-centric services. These include a no-cost mobile phlebotomy program for liquid biopsy testing, a patient financial assistance program based on federal poverty guidelines, and various payment choices to ensure accessibility to their diagnostic services.